naa a22 4500 510764576 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1033-1 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1033-1 Zoledronic acid in genitourinary cancer [Elektronische Daten] [M. Climent, U. Anido, M. Méndez-Vidal, J. Puente] Bone metastases are a common complication of advanced prostate cancer and while they are less common in non-prostate genitourinary (GU) malignances, they have been reported in up to 35% of patients with advanced renal cell carcinoma and bladder cancer. Furthermore, they may occur in more than two-thirds of those patients with bladder cancer who develop distant metastases. In the absence of bone-targeted therapies, approximately 50% of all patients with metastatic bone disease from GU cancers experience at least one skeletal-related event within their lifetime. Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients. Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Zoledronic acid nationallicence Genitourinary cancer nationallicence Kidney cancer nationallicence Urothelial cancer nationallicence Climent M. Servicio de Oncología Médica, Instituto Valenciano de Oncología (IVO), C/Beltrán Báguena, 8, 46009, Valencia, Spain aut Anido U. Servicio de Oncología Médica, Complejo Hospitalario Universitario Santiago de Compostela, A Coruña, Spain aut Méndez-Vidal M. Servicio de Oncología Médica, Hospital Reina Sofía, Córdoba, Spain aut Puente J. Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 871-878 1699-048X 15:11<871 2013 15 12094 https://doi.org/10.1007/s12094-013-1033-1 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1033-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Climent M. Servicio de Oncología Médica, Instituto Valenciano de Oncología (IVO), C/Beltrán Báguena, 8, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Anido U. Servicio de Oncología Médica, Complejo Hospitalario Universitario Santiago de Compostela, A Coruña, Spain aut NATIONALLICENCE 700 1- Méndez-Vidal M. Servicio de Oncología Médica, Hospital Reina Sofía, Córdoba, Spain aut NATIONALLICENCE 700 1- Puente J. Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 871-878 1699-048X 15:11<871 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer